Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 21, Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and raised the price target from $84 to $96
This valuation adjustment is based on the growing institutional confidence in the underlying investment case for GTX-102, which is used to treat Angelman syndrome. Tonhom1009/ Due to highly favorable testing parameters, Kluska says that the clinical asset now shows a significantly higher likelihood of eventual success. This optimistic assessment is heavily driven by the specific structural design of its Phase 3 trial.
Specifically, the comprehensive evaluation utilizes the Bayley-4 cognitive raw score alongside the MDRI metric to measure efficacy. By organizing the clinical architecture in this manner, it can successfully establish two entirely independent pathways to achieve formal statistical success, thereby mitigating developmental risk and strengthening the broader product portfolio. On May 8, the price target on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was reduced by Wedbush from $27 to $26, which still yields almost 14% upside at the current level.